Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

Ning Liu,Zimin Liu,Yanbing Zhou,Zhaojian Niu,Haitao Jiang,Yingqian Zhu,Huiyun Wang,Xiaoxiao Li,Shanai Song,Xiaodong Liu,Zequn Li,Shufen Zhao

Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

2021

Ning Liu
Zimin Liu
Yanbing Zhou
Zhaojian Niu
Haitao Jiang
Yingqian Zhu
Huiyun Wang
Xiaoxiao Li
Shanai Song
Xiaodong Liu
Zequn Li
Shufen Zhao

e16020Background: Docetaxel-based neoadjuvant chemotherapy has been suggested to be beneficial in patients with locally advanced gastric and gastro-oesophageal junction cancer (GC/GEJC). And immuno...

Keywords:

locally advanced
in patient
Docetaxel
Oncology
Internal medicine
Cancer
Medicine
Chemotherapy
Radical gastrectomy
Gastroesophageal Junction Adenocarcinoma
Neoadjuvant therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations